The study drew on 321 men from the MACS/WIHS Combined Cohort Study, one of the longest-running observational research programs on HIV in the United States. Roughly 65 percent of the participants were living with HIV, and the group’s median age was 62 years. Using high-resolution B-mode ultrasound, the investigators examined each participant’s carotid arteries, the large vessels that carry blood to the brain, and looked for plaque buildup with an arterial wall thickness exceeding 1.5 millimeters, the standard marker of subclinical atherosclerosis, meaning artery disease that has not yet caused symptoms. Just under a third of the men, 31.5 percent, had detectable carotid plaque.

What makes the study methodologically striking is its layered design. The researchers first measured 14 serum sex hormones along with sex hormone-binding globulin, or SHBG, the glycoprotein that binds sex steroids in the bloodstream and regulates how much free, biologically active hormone circulates in the body. Then, in a subset of 312 men, they profiled 986 plasma metabolites using liquid chromatography-tandem mass spectrometry, a technique that separates and identifies small molecules with high precision, and quantified 2,883 plasma proteins on the Olink Explore 3072 platform, an affinity-based proteomics assay that measures proteins across inflammatory, metabolic, and cardiovascular pathways. Stool samples underwent metagenomic sequencing, allowing the team to identify gut microbial species and their relative abundances.

The central question was whether sex hormones relate to artery plaque differently in men with HIV compared with men without it, and whether the molecular fingerprints of those hormones might explain the connection. The team built what they call omics scores: linear combinations of the gut microbial species, metabolites, and proteins most strongly associated with a given hormone. If a hormone’s downstream molecular signature is also linked to plaque, that signature offers clues about mechanism, not just correlation.

The headline result concerned SHBG. In men with HIV, each one-standard-deviation increase in SHBG was associated with 40 percent lower odds of carotid plaque, with an odds ratio of 0.60 and a 95 percent confidence interval of 0.41 to 0.90. No such protective association appeared in the men without HIV, and the pattern of associations for the other sex hormones diverged between the two groups as well, hinting that HIV itself, or its long-term interplay with antiretroviral therapy and chronic immune activation, alters how the endocrine system relates to vascular health.

The multi-omics layer then revealed what SHBG is traveling with. Higher SHBG levels tracked with a measurably different overall gut microbial composition, including lower abundance of species from the genera Prevotella, Fibrobacter, and Coprococcus. They also tracked with higher levels of certain circulating metabolites, predominantly lipids and carnitine-related compounds, molecules that sit at the intersection of fat transport and mitochondrial energy metabolism, and with a protein profile enriched in the cell-cell adhesion pathway, the molecular machinery that governs how immune cells stick to blood vessel walls, a key early step in plaque formation.

Crucially, several of the individual molecules associated with SHBG were themselves associated with plaque in men with HIV. The microbial species Mediterranea massiliensis, phosphatidylcholine-based lipids, and proteins involved in immune response pathways all appeared in both lists, connecting SHBG to artery disease through three independent biological domains. When the researchers consolidated this signal into the three omics scores, the results converged: all three scores were inter-correlated with one another and each was inversely associated with carotid plaque in men with HIV. A species score, a metabolite score, and a protein score, built from completely different measurement technologies, all pointing the same direction.

The contrast group told a different story. Among men without HIV, the only significant hormone-plaque link was estrone-sulfate, a sulfated form of estrogen, which was positively associated with plaque, with an odds ratio of 3.80 and a 95 percent confidence interval of 1.41 to 10.22. Notably, estrone-sulfate showed no associations with any gut microbial species, metabolites, or proteins, suggesting its relationship to artery disease may run through a different mechanism, or that the study lacked the statistical power to detect one. This asymmetry between the two groups is one of the paper’s most provocative implications: the cardiovascular meaning of a given hormone appears to depend on HIV status.

The findings carry real-world weight because people living with HIV face an elevated burden of cardiovascular disease that traditional risk calculators do not fully capture. Even with viral suppression maintained by antiretroviral therapy, chronic inflammation, immune dysregulation, and metabolic changes persist, and heart attacks and strokes occur more often than expected. If SHBG, a molecule that can be measured cheaply in serum, genuinely marks, or perhaps mediates, a protective vascular state in this population, it could become part of risk stratification and eventually a therapeutic target.

The word “perhaps” matters here. This is a cross-sectional observational study: hormones and omics profiles and plaque were measured at the same time, so the data cannot prove that high SHBG causes less plaque. Reverse causation is plausible, since systemic illness, inflammation, and metabolic dysfunction are known to lower SHBG levels, meaning that plaque itself could conceivably drag the protein down. The authors’ exploratory mediation analyses, testing whether the omics scores statistically explain the SHBG-plaque association, are suggestive rather than definitive. Longitudinal follow-up, and ideally interventions that raise SHBG, would be needed to establish causality.

Still, the study exemplifies where cardiovascular research is heading. Rather than testing a single biomarker against a single outcome, the multi-omics approach maps the shadow a molecule casts across the gut microbiome, the metabolome, and the proteome, then checks whether those shadows fall on disease itself. SHBG, often treated as a passive transport protein, emerges from this analysis as a hub connected to gut ecology, lipid metabolism, carnitine handling, and vascular immune biology. Whether the protective signal holds over time, and whether it extends to women with HIV and other populations, will be the natural next questions. For now, the study offers men living with HIV a new molecular clue to a persistent clinical puzzle: why their arteries age faster than their calendar risk factors predict.

The human gut is host to trillions of microorganisms, including bacteria, archaea, viruses, and fungi, collectively known as the gut microbiome. These microorganisms execute vital functions such as nutrient metabolism, immune regulation, and maintenance of intestinal barrier integrity. However, their influence extends beyond the gastrointestinal tract through the production of metabolites and signaling molecules that affect distant organs, including the kidneys and heart. This study harnesses multi-omics approaches alongside longitudinal clinical data to decode this elaborate communication network and identify specific microbial signatures predictive of cardiovascular risk.

Central to the findings is the identification of distinct microbial taxa and their metabolites that appear to drive pathogenic pathways by modulating renal function, subsequently influencing cardiac health. Traditionally, the kidneys and heart have been viewed through a cardiorenal lens, where dysfunction in one organ exacerbates injury in the other. Chechi and colleagues expand this paradigm by incorporating the gut microbiome as a critical upstream regulator. Their analysis reveals that dysbiosis—microbial community imbalance—increases generation of uremic toxins and pro-inflammatory metabolites which impair glomerular filtration and promote vascular endothelial dysfunction.

Mechanistically, the study elucidates how microbial metabolites like trimethylamine-N-oxide (TMAO), indoxyl sulfate, and p-cresyl sulfate act as mediators in this axis. Elevated levels of these metabolites, frequently produced by gut bacteria metabolizing dietary choline and protein, enter systemic circulation, where they exacerbate oxidative stress, inflammation, and fibrosis within renal tissues. The resulting kidney impairment perturbs fluid and electrolyte homeostasis, which in turn places significant hemodynamic strain on the myocardium, fostering heart failure and arrhythmogenesis.

Importantly, the authors demonstrate that longitudinal profiling of gut microbial composition combined with plasma metabolomics can accurately stratify patients at risk for future cardiovascular events even before overt clinical manifestations. This predictive capacity, backed by rigorous machine learning models trained on high-dimensional datasets, offers a potential paradigm shift in preventive cardiology. By integrating microbiome analyses into routine diagnostics, clinicians could preemptively identify high-risk individuals, enabling early intervention strategies and personalized treatment plans.

The study further dissects the immune-modulatory roles of the gut microbiome within this axis, highlighting its influence on systemic inflammation—a recognized driver of atherosclerosis and myocardial injury. Alterations in the gut microbial population were correlated with shifts in circulating cytokine profiles, including increased levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Such pro-inflammatory states intensify endothelial dysfunction and plaque instability, underpinning the increased susceptibility to ischemic events observed in the study cohort.

Chechi et al.’s work also underscores the kidney’s role as both a filter and a responder to microbiome-derived metabolites, showcasing how renal clearance of these compounds determines their systemic concentrations and consequent cardiovascular impact. Their analysis detailed renal transcriptomic changes induced by elevated microbial metabolites, highlighting the activation of profibrotic pathways such as transforming growth factor-beta (TGF-β) signaling, which promote glomerulosclerosis and chronic kidney disease progression.

Clinically, this research calls for a reassessment of therapeutic strategies targeting cardiovascular risk. Current treatments focusing on blood pressure and lipid control could be augmented by interventions modulating the gut microbiome—such as probiotics, prebiotics, dietary modifications, and even targeted bacteriophage therapy. By restoring microbial balance and reducing the load of toxic metabolites, it may be possible to ameliorate kidney impairment and thereby safeguard cardiac function.

Furthermore, the study ventures into the potential of personalized microbiome-based therapies, emphasizing the interindividual variability in microbial composition and metabolite production. This variability necessitates patient-specific microbial profiling to tailor interventions effectively. The prospect of developing microbial metabolite inhibitors or adsorbents to reduce systemic toxin levels emerges as a promising avenue for future drug development.

Technological advances underpinning this research were pivotal. The integration of shotgun metagenomics with high-throughput metabolomics and single-cell RNA sequencing enabled a comprehensive assessment of functional microbiome-host interactions. Coupled with sophisticated bioinformatics pipelines and robust statistical modeling, these tools allowed the authors to distill complex datasets into actionable biological insights.

While the study presents compelling evidence linking the gut microbiome-kidney-heart axis to cardiovascular disease risk, it also opens new questions. The directionality and causality of these interrelationships warrant further exploration through interventional trials. Additionally, the environmental and lifestyle factors influencing microbial composition and metabolite production in the context of this axis remain an area ripe for investigation.

In a global health landscape where cardiovascular diseases remain the leading cause of mortality, this research offers a beacon of hope. It illuminates previously underappreciated molecular conduits connecting gut microbes, renal function, and cardiac health, underscoring the systemic nature of cardiovascular pathology. By advancing our grasp of these intricate biological networks, it paves the way for transformative advances in prevention, diagnosis, and therapeutics.

The implications extend beyond cardiology into nephrology and gastroenterology, advocating for a multidisciplinary approach to patient care. Healthcare practitioners are encouraged to recognize the gut microbiome as a dynamic organ influencing systemic health. This recognition advocates for integrating microbiome assessments into routine clinical evaluation and designing multifaceted treatment regimens addressing microbial dysbiosis alongside traditional risk factors.

In conclusion, the study by Chechi et al. marks a paradigm shift, positioning the gut microbiome not merely as a bystander but as a key orchestrator in the pathophysiology of cardiovascular diseases via a novel kidney-heart axis. This intricate crosstalk offers unprecedented opportunities for early detection and intervention, reshaping future cardiovascular medicine into a more holistic, systems-biology oriented discipline. Harnessing the full potential of this axis will undoubtedly require continued collaborative research, technological innovation, and clinical translation, but the pathway illuminated by this work is poised to redefine our battle against cardiovascular disease.

Subject of Research: The gut microbiome’s role in modulating kidney function and heart health, with implications for predicting future cardiovascular diseases.

Article Title: A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases

Article References:
Chechi, K., Chakaroun, R., Myridakis, A. et al. A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases. Nat Commun (2026). https://doi.org/10.1038/s41467-026-69405-0

Image Credits: AI Generated

The gut microbiome, which consists of trillions of microorganisms, has emerged as a key player in a variety of bodily functions, including metabolism, immune function, and even cardiovascular health. This study aims to shed light on the less explored dimension of how these microorganisms might respond differently in males and females, influencing the overall risk of developing CAD. Different structures and compositions of gut microbiota suggest that men and women experience varying risks when it comes to heart disease.

Among the most striking revelations of the study is the observation that women report different symptoms and outcomes in heart disease compared to men, irrespective of conventional risk factors such as age, smoking, or high blood pressure. This observation invites a deeper exploration into the lesser-known determinants that may be contributing to these differences. Researchers have posited that sex hormones, particularly estrogen and testosterone, exert significant influence over the composition and function of the gut microbiome.

Estrogen, for instance, has been shown to enrich certain beneficial bacteria such as Lactobacillus, which plays a crucial role in maintaining gut health. In contrast, testosterone has been linked to an increased presence of bacteria associated with inflammation. These hormonal variations are not simply byproducts of biological differences but may actively shape the gut environment, influencing how cardiovascular diseases develop and manifest in each sex.

The researchers conducted an extensive review of existing literature, synthesizing data and findings from various studies that explore the gut-heart axis. They identified that bacterial metabolites, such as short-chain fatty acids, might have different impacts on men’s and women’s cardiovascular systems. For example, some metabolites have been linked with anti-inflammatory properties, while others could potentially lead to increased cardiovascular risks. This nuanced understanding holds groundbreaking implications for personalized medicine approaches, particularly in treating and preventing CAD.

Moreover, the study emphasizes the potential of diet as a modifying factor that interacts with the gut microbiome. The researchers elaborated on how women tend to have different dietary patterns than men, affecting microbial profiles significantly. Diets rich in fiber and fermented foods are shown to boost beneficial bacteria, which can mitigate the risk factors associated with CAD. This highlights the potential for dietary interventions to tailor health strategies specifically for each sex and thereby enhance cardiovascular health outcomes.

In examining the gut-heart relationship, the review does not shy away from discussing additional psychosocial factors—like stress and mood—that may further complicate the sex differences in coronary artery disease. Greater social support, for example, has been linked to healthier lifestyle choices and better heart health outcomes, particularly in women. This intersection of psychological health and cardiovascular outcomes presents an opportunity for future research that could deepen our understanding of heart disease prevention.

The implications of discovering these microbial and metabolic disparities cannot be overstated. As healthcare continues to evolve toward a more personalized approach, understanding how sex plays a role in diseases like CAD could lead to the development of targeted therapies. This may involve the creation of specific probiotics or dietary recommendations that cater to either men or women based on their unique gut microbiome profiles, ultimately improving outcomes in heart disease.

The analysis also points out a significant gap in existing clinical guidelines that often overlook these crucial sex-based differences. By failing to consider such disparities, medical professionals may be underestimating the risk factors for female patients, who might experience different symptoms or more atypical presentations of coronary artery disease. The study emphasizes the need for increased awareness among clinicians regarding these differences in order to deliver more effective and equitable healthcare.

As researchers delve deeper into the complex interplay of the gut microbiome and cardiovascular health, the study serves as a clarion call for further investigations into how best to harness this knowledge for clinical advantage. These findings pave the way for exciting advancements in understanding cardiovascular health. In the near future, it is conceivable that treatment strategies will evolve to account not only for traditional risk factors but also for the unique microbial signatures present in male and female patients.

In conclusion, this comprehensive examination of the gut-heart axis is a vital contribution to the ongoing dialogue about sex differences in health and disease. As the field of microbiome research continues to expand, it holds the promise of unlocking new avenues for the prevention, diagnosis, and treatment of coronary artery disease. The study not only affirms the relevance of sex as a biological variable but also sets the stage for future innovations that could profoundly improve patient care in cardiovascular health.

This innovative research activates a rethinking of the strategies employed by healthcare practitioners as they navigate the complexities of heart disease. As we gain further insights into the link between the gut microbiome and cardiovascular disease outcomes, it is essential to integrate this knowledge into clinical practice to ensure comprehensive and tailored patient care moving forward.

Subject of Research: The connection between gut microbiota and coronary artery disease with a focus on sex-based disparities.

Article Title: The gut–heart axis in coronary artery disease: a scoping and narrative review of sex-based microbial and metabolic disparities.

Article References: Chong-Nguyen, C., Artiles, R.F., Pilgrim, T. et al. The gut–heart axis in coronary artery disease: a scoping and narrative review of sex-based microbial and metabolic disparities. Biol Sex Differ (2026). https://doi.org/10.1186/s13293-026-00824-w

Image Credits: AI Generated

DOI:

Keywords: Gut microbiome, coronary artery disease, sex disparities, personalized medicine, gut-heart axis.